Catalyst Pharmaceuticals’ (CPRX) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has a $30.00 target price on the biopharmaceutical company’s stock. Several other brokerages have also recently issued reports on CPRX. Citigroup raised their price objective on […]
More Stories
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Large Decrease in Short Interest
SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report) was the target of a significant decrease in short interest in the...
Valmet Oyj (OTCMKTS:VOYJF) Sees Large Decrease in Short Interest
Valmet Oyj (OTCMKTS:VOYJF – Get Free Report) was the recipient of a significant drop in short interest during the month...
Ubisoft Entertainment SA (OTCMKTS:UBSFY) Sees Significant Decrease in Short Interest
Ubisoft Entertainment SA (OTCMKTS:UBSFY – Get Free Report) was the target of a large drop in short interest in the...
SecureWorks Corp. (NASDAQ:SCWX) Short Interest Down 33.4% in October
SecureWorks Corp. (NASDAQ:SCWX – Get Free Report) was the target of a significant drop in short interest in October. As...
SecureWorks Corp. (NASDAQ:SCWX) Short Interest Down 33.4% in October
SecureWorks Corp. (NASDAQ:SCWX – Get Free Report) was the target of a significant drop in short interest in October. As...
SLM Co. (NASDAQ:SLMBP) Short Interest Update
SLM Co. (NASDAQ:SLMBP – Get Free Report) was the recipient of a large drop in short interest in October. As...